Atricure, INC DEF 14A proxy statements

AtriCure, Inc. has released its 2026 proxy statement detailing proposals for director elections, executive compensation, and increases to equity incentive plans.

AtriCure urges stockholders to approve its Say-on-Pay proposal, addressing concerns raised by ISS and Glass Lewis regarding executive compensation, particularly the CEO's special performance share unit award.

AtriCure, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

AtriCure, Inc. has announced its 2025 Annual Meeting of Stockholders to be held virtually on May 19, 2025, and is seeking stockholder approval for several proposals, including an amendment to the 2023 Stock Incentive Plan.

AtriCure is urging its stockholders to vote in favor of its Say-on-Pay proposal at the upcoming Annual Meeting, despite a recommendation against it from proxy advisory firm Glass Lewis.

AtriCure urges stockholders to approve a proposal to amend its certificate of incorporation to limit officer liability, countering a recommendation from Glass Lewis.

AtriCure, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

AtriCure's proxy statement outlines proposals for the 2024 annual meeting, including limiting officer liability and increasing shares for the stock incentive plan.